|Systematic (IUPAC) name|
|Trade names||Claforan ; Cefatam (LGls)|
|Routes||Intravenous and Intramuscular|
|Molecular mass||455.47 g/mol|
|(what is this?)|
Cefotaxime (INN) // is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, cefotaxime is a broad-spectrum antibiotic with activity against numerous Gram-positive and Gram-negative bacteria. Developed by Hoechst-Roussel Pharmaceuticals in the late 1980s, it was among the first third generation ("extended spectrum") cephalosporins and the first of its class to become available in the United States. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.
Given its broad spectrum of activity, cefotaxime is used for a variety of infections, including:
- Lower respiratory tract infections - e.g. pneumonia (most commonly caused by S. pneumoniae)
- Genitourinary system infections - urinary tract infections (e.g. E. coli, S. epidermidis, P. mirabilis) and cervical/urethral gonorrhea
- Gynecologic infections - e.g. pelvic inflammatory disease, endometritis, and pelvic cellulitis
- Bacteremia/septicemia - secondary to Streptococcus spp., S. aureus, E. coli, and Klebsiella spp.
- Intra-abdominal infections - e.g. peritonitis
- Bone and join infections - S. aureus, Streptococcus spp.
- CNS infections - e.g. meningitis/ventriculitis secondary to N. meningitidis, H. influenzae, S. pneumoniae
Although cefotaxime has demonstrated efficacy in these infections, it is not necessarily considered to be the first-line agent. In meningitis, cefotaxime crosses the blood–brain barrier better than cefuroxime.
Spectrum of activity
As a β-lactam antibiotic in the third-generation class of cephalosporins, cefotaxime is active against numerous Gram-positive and Gram-negative bacteria, including several with resistance to classic β-lactams such as penicillin. These bacteria often manifest as infections of the lower respiratory tract, skin, central nervous system, bone, and intra-abdominal cavity. While regional susceptibilities must always be considered, cefotaxime typically is effective against these organisms (in addition to many others):
- Staphylococcus aureus (not including MRSA) and S. epidermidis
- Streptococcus pneumoniae and S. pyogenes
- Escherichia coli
- Haemophilus influenzae
- Neisseria gonorrhoeae and N. meningitidis
- Klebsiella spp.
- Proteus mirabilis and P. vulgaris
- Enterobacter spp.
- Bacteroides spp.
- Fusobacterium spp.
The following represents MIC susceptibility data for a few medically significant microorganisms:
- Haemophilus influenzae: ≤0.007 - 0.5 µg/ml
- Staphylococcus aureus: 0.781 - 172 µg/ml
- Streptococcus pneumoniae: ≤0.007 － 8 µg/ml
Historically, cefotaxime has been considered to be comparable to ceftriaxone (another third-generation cephalosporin) in safety and efficacy for the treatment of bacterial meningitis, lower respiratory tract infections, skin and soft tissue infections, genitourinary tract infections, and bloodstream infections, as well as prophylaxis for abdominal surgery. The majority of these infections are caused by organisms traditionally sensitive to both cephalosporins. However, ceftriaxone has the advantage of once-daily dosing, whereas the shorter half-life of cefotaxime necessitates two or three daily doses for efficacy. Changing patterns in microbial resistance suggest cefotaxime may be suffering greater resistance than ceftriaxone, whereas the two were previously considered comparable. It is also important to consider regional microbial sensitivities when choosing any antimicrobial agent for the treatment of infection.
Cefotaxime is contraindicated in patients with a known hypersensitivity to cefotaxime or other cephalosporins. Caution should be used and risks weighed against potential benefits in patients with an allergy to penicillin, due to cross-reactivity between the classes.
The most common adverse reactions experienced are:
- Pain and inflammation at the site of injection/infusion (4.3%)
- Rash, pruritus, or fever (2.4%)
- Colitis, diarrhea, nausea, vomiting (1.4%)
Mechanism of action
Cefotaxime is a β-lactam antibiotic (which refers to the structural components of the drug molecule itself). As a class, β-lactams inhibit bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs). This inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) in the absence of cell wall assembly. Due to the mechanism of their attack on bacterial cell wall synthesis, β-lactams are considered to be bactericidal.
Unlike β-lactams such as penicillin and amoxicillin, which are highly susceptible to degradation by β-lactamase enzymes (produced, for example, nearly universally by S. aureus), cefotaxime boasts the additional benefit of resistance to β-lactamase degradation due to the structural configuration of the cefotaxime molecule. The syn-configuration of the methoxyimino moiety confers stability against β-lactamases. Consequently, the spectrum of activity is broadened to include several β-lactamase-producing organisms (which would otherwise be resistant to β-lactam antibiotics), as outlined below.
Cefotaxime, like other β-lactam antibiotics, does not only block the division of bacteria, including cyanobacteria, but also the division of cyanelles, the photosynthetic organelles of the glaucophytes, and the division of chloroplasts of bryophytes. In contrast, it has no effect on the plastids of the highly developed vascular plants. This supports the endosymbiotic theory and indicates an evolution of plastid division in land plants.
Cefotaxime is administered by intramuscular injection or intravenous infusion. As cefotaxime is metabolized to both active and inactive metabolites by the liver and largely excreted in the urine, dose adjustments may be appropriate in people with renal or hepatic impairment.
Plant tissue culture
Cefotaxime is the only cephalosporin which has very low toxicity in plants, even at higher concentration (up to 500 mg/l). It is widely used to treat plant tissue infections with Gram-negative bacteria, while vancomycin is used to treat the plant tissue infections with Gram-positive bacteria.
- Scriabine, Alexander (1999). "Chapter 2.". In Landau, Ralph; Achilladelis, Basil; Scriabine, Alexander. Pharmaceutical Innovation: Revolutionizing Human Health. Pennsylvania: Chemical Heritage Foundation. p. 169. ISBN 0-941901-21-1. Retrieved 2015-01-17.
- "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.
- U.S. Food and Drug Administration. U.S. Department of Health and Human Services. Claforan Sterile (cefotaxime for injection, USP) and Injection (cefotaxime injection, USP). 19 June 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050596s035,050547s066lbl.pdf
- Cefotaxime drug information
- http://antibiotics.toku-e.com/antimicrobial_463_19.html[full citation needed]
- http://www.toku-e.com/Assets/MIC/Cefotaxime%20sodium%20USP.pdf[full citation needed]
- Scholz H, Hofmann T, Noack R, Edwards DJ, Stoeckel K (1998). "Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children". Chemotherapy 44 (2): 142–7. PMID 9551246.
- Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden AJ, Solomon C, Bolt D (January 2003). "A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery". American Journal of Surgery 185 (1): 45–9. doi:10.1016/S0002-9610(02)01125-X. PMID 12531444.
- Simmons BP, Gelfand MS, Grogan J, Craft B (1995). "Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections". Diagnostic Microbiology and Infectious Disease 22 (1-2): 155–7. doi:10.1016/0732-8893(95)00080-T. PMID 7587031.
- Gums JG, Boatwright DW, Camblin M, Halstead DC, Jones ME, Sanderson R (January 2008). "Differences between ceftriaxone and cefotaxime: microbiological inconsistencies". The Annals of Pharmacotherapy 42 (1): 71–9. doi:10.1345/aph.1H620. PMID 18094350.
- Van TT, Nguyen HN, Smooker PM, Coloe PJ (March 2012). "The antibiotic resistance characteristics of non-typhoidal Salmonella enterica isolated from food-producing animals, retail meat and humans in South East Asia". International Journal of Food Microbiology 154 (3): 98–106. doi:10.1016/j.ijfoodmicro.2011.12.032. PMID 22265849.
- Kasten B, Reski R (1997). "β-Lactam antibiotics inhibit chloroplast division in a moss (Physcomitrella patens) but not in tomato (Lycopersicon esculentum)". Journal of Plant Physiology 150 (1–2): 137–40. doi:10.1016/S0176-1617(97)80193-9. INIST:2640663.
- Bertels RA, Semmekrot BA, Gerrits GP, Mouton JW (October 2008). "Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusion". Infection 36 (5): 415–20. doi:10.1007/s15010-008-7274-1. PMID 18791659.
- Coombes JD (1982). "Metabolism of cefotaxime in animals and humans". Reviews of Infectious Diseases 4 (Suppl 2): S325–32. doi:10.1093/clinids/4.Supplement_2.S325. JSTOR 4452886. PMID 6294781.
- cefotaxime for plant tissue culture
- vancomycin for plant cell culture
- Pazuki, A; Asghari, J; Sohani, M; Pessarakli, M & Aflaki, F (2014). "Effects of Some Organic Nitrogen Sources and Antibiotics on Callus Growth of Indica Rice Cultivars" (PDF). Journal of Plant Nutrition 00 (0): 00–00. doi:10.1080/01904167.2014.983118. Retrieved February 17, 2014.